Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2
The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be
influenced by individual clinical features or by patterns of risk factors and comorbidities. We …
influenced by individual clinical features or by patterns of risk factors and comorbidities. We …
Prevalent new‐user cohort designs for comparative drug effect studies by time‐conditional propensity scores
S Suissa, EEM Moodie… - … and drug safety, 2017 - Wiley Online Library
Purpose Studies of the real‐world comparative effectiveness of drugs conducted using
computerized healthcare databases typically involve an incident new‐user cohort design for …
computerized healthcare databases typically involve an incident new‐user cohort design for …
Effectiveness and safety of non–vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses
Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …
Overview of the new oral anticoagulants: opportunities and challenges
The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin for many
indications. These agents include dabigatran, which inhibits thrombin, and rivaroxaban …
indications. These agents include dabigatran, which inhibits thrombin, and rivaroxaban …
Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban …
G Maura, PO Blotière, K Bouillon, C Billionnet… - Circulation, 2015 - Am Heart Assoc
Background—The safety and effectiveness of non–vitamin K antagonist (VKA) oral
anticoagulants, dabigatran or rivaroxaban, were compared with VKA in anticoagulant-naive …
anticoagulants, dabigatran or rivaroxaban, were compared with VKA in anticoagulant-naive …
Risk of gastrointestinal bleeding in patients taking non–vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis
Background & Aims Non–vitamin K antagonist oral anticoagulants (NOACs) are convenient
and effective in the prevention and treatment of venous thromboembolism and the …
and effective in the prevention and treatment of venous thromboembolism and the …
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013
Aims Non-vitamin K antagonist oral anticoagulation (NOAC) agents have been approved for
stroke prophylaxis in atrial fibrillation (AF). We investigated 'real-world'information on how …
stroke prophylaxis in atrial fibrillation (AF). We investigated 'real-world'information on how …
Cause of death and predictors of all‐cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF
SD Pokorney, JP Piccini, SR Stevens… - Journal of the …, 2016 - Am Heart Assoc
Background Atrial fibrillation is associated with higher mortality. Identification of causes of
death and contemporary risk factors for all‐cause mortality may guide interventions …
death and contemporary risk factors for all‐cause mortality may guide interventions …
Major bleeding complications and persistence with oral anticoagulation in non‐valvular atrial fibrillation: contemporary findings in real‐life Danish patients
M Lamberts, L Staerk, JB Olesen… - Journal of the …, 2017 - Am Heart Assoc
Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …
Stroke and major bleeding risk in elderly patients aged≥ 75 years with atrial fibrillation: the Loire Valley atrial fibrillation project
Background and Purpose—Atrial fibrillation (AF) is increasingly prevalent in the elderly, but
such patients tend to be under-represented in clinical trials. Increasing age confers a higher …
such patients tend to be under-represented in clinical trials. Increasing age confers a higher …